PRME

3.5657.16%
DR

David R. Liu

Co-Founder & Member of Scientific Advisory Board

Dr. David R. Liu, PhD., is Founder of nChroma Bio. Dr. Liu is Co-Founder of Pairwise Plants, LLC. He is Member of Scientific Advisory Board of Genscript Biotech Corporation since March 2024. Dr. Liu is Founder at Chroma Medicine, Inc. Dr. Liu was Member of Scientific Advisory Board of Voyager Therapeutics, Inc. He has been a Co-Founder at Prime Medicine, Inc and served as its Chairman of Scientific Advisory Board since August 2022 until October 2024. He serves as Member of Scientific Advisory Board at Insitro, Inc. since May 2022. He had been a Member of Scientific Advisory Board at WuXi Biologics (Cayman) Inc. since September 25, 2018. He served as Director of the Merkin Institute, Core Institute Member and Vice-Chair of the Faculty at the Broad Institute and Howard Hughes Medical Institute (HHMI) Investigator. He is a Co-Founder & Member of Scientific Advisory Board of Exo Therapeutics, Inc. He is the Co-Founder of Beam Therapeutics Inc. He Co-Founded Editas Medicine Inc. in 2013 and served as its Scientific Advisory Board Member. Dr. Liu has been Founding Scientist at Permeon Biologics, Inc. since 2010 and serves as its Scientific Advisory Board Chairman and Board Observer. He serves as Howard Hughes Medical Institute Investigator at Harvard University. Dr. Liu is a Professor of Chemistry and Chemical Biology at Harvard University. He served as Member of Scientific Advisory Board at Moderna Therapeutics, Inc. Dr. Liu served as a Member of Scientific Advisory Board of Codon Devices, Inc. and Helicos BioSciences Corporation. He was promoted to Full Professor and became an HHMI Investigator in 2005. He serves as Member of Scientific Advisory Board at Tevard Biosciences LLC. He served as a Director at Editas Medicine Inc. Dr. Liu was an Assistant Professor of Chemistry and Chemical Biology at Harvard University since 1999. The notable contributions of Dr. Liu's laboratory include the invention of two precise gene editing methods that do not require double-stranded DNA breaks: base editing, a groundbreaking method for the precise introduction of single-letter gene edits and prime editing, a highly versatile genome editing technology that installs precise substitutions, insertions, or deletions and is inherently resistant to off-target editing. His research through the use of phage-assisted continuous evolution (PACE) has paved the way for the discovery of proteins with novel therapeutic potential and his pioneering of DNA-encoded small-molecule libraries laid a foundation for the current use of DNA-encoded libraries to accelerate drug discovery. Dr. Liu, Professor at Harvard University, Broad Institute and Howard Hughes Medical Institute, holds numerous prestigious awards and has been elected to the U.S. National Academy of Sciences, the U.S. National Academy of Medicine and the American Association for the Advancement of Science. His over 258 publications and more than 105 issued U.S. patents demonstrate his commitment and influence in the fields of chemistry, biology and therapeutics. Dr. Liu's research applies evolutionary principles to the creation and evaluation of small molecules and macromolecules. His research interests include the development and application of new approaches to the evolution of biological macromolecules and the application of evolutionary principles to the discovery of synthetic small molecules, synthetic polymers and new chemical reactions. He has received distinctions including the American Chemical Society Pure Chemistry Award, the American Chemical Society Arthur C. Cope Young Scholar Award, the GlaxoSmithKline Chemistry Scholar Award, the AstraZeneca Pharmaceuticals Excellence in Chemistry Award, the Searle Scholars Award, the NSF CAREER Award, the Sloan Foundation Fellowship, the Beckman Foundation Young Investigator Award, the Office of Naval Research Young Investigator Award and the university-wide Roslyn Abramson Award for undergraduate teaching at Harvard. He was named to the Popular Science Brilliant 10 for young scientists in the United States, as well as to the MIT TR100 for young innovators. He is the Founder of Pairwise Plants. His accomplishments also include groundbreaking research into DNA-templated drug discovery, leading to the foundation of Cambridge, MA-based Ensemble Therapeutics. Dr. Liu received a B. A. in Chemistry from Harvard College and a Ph.D. in Organic Chemistry from the University of California, Berkeley in 1999. He advises and Co-founded SeQure Dx and Verve Therapeutics. His research and teaching have earned distinctions including the Ronald Breslow Award, the Pure Chemistry Award and the Arthur C. Cope Scholar Award. In 2017, he was named to the Nature's 10 researchers in world and base editing, a next-generation genome editing technology, was one of four finalists for Science magazine's 2017 Breakthrough of the Year. He graduated in 1994 at Harvard, where he performed research on sterol biosynthesis under Professor E. J. Corey's guidance. He earned his Ph.D. in 1999 and became Assistant Professor at Harvard.

Positions